Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli. These vaccines are distributed across Europe, North America, Canada and select emerging markets through a network of subsidiaries and distribution partners. Valneva’s product portfolio also includes earlier-stage candidates targeting Lyme disease, chikungunya and other vector-borne diseases, as well as a vaccine program against COVID-19.
The company was formed in 2013 through the merger of Austrian-based Intercell AG and French biotech Vivalis SA, combining expertise in vaccine research and manufacturing. Valneva is dual-listed on Euronext Paris and the Nasdaq Stock Market, reflecting its ambition to serve both European and U.S. public health markets. Its manufacturing facilities are located in Scotland, Sweden, Austria and the United States, supporting both clinical and commercial vaccine supply.
Valneva is led by Chief Executive Officer Thomas Lingelbach, whose background in biopharmaceutical development guides the company’s strategic priorities. Under his leadership, Valneva continues to expand its pipeline, strengthen global partnerships and invest in capacity to respond to future infectious disease challenges.
AI Generated. May Contain Errors.
